Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1445 - 1445
Published: Oct. 29, 2024
Bacterial vaginosis (BV), an infection caused primarily by
Language: Английский
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1521 - 1521
Published: Feb. 24, 2025
Background/Objectives: Persistent high-risk human papillomavirus (HPV) infections are the leading cause of cervical cancer. Developing evidence suggests that cervicovaginal microbiome plays a significant role in modulating HPV persistence and progression to neoplasia. This review synthesizes current knowledge on interplay between local immunity infections, emphasizing microbial diversity, immune responses, potential therapeutic implications. Methods: A thorough literature was performed using Embase, PubMed, Scopus, Google Scholar, encompassing studies published 2000 2024. Studies examining composition microbiome, HPV-related outcomes were evaluated synthesized into comprehensive review. Results: Lactobacillus-dominant particularly with L. crispatus, creates protective environment through lactic acid production, maintenance low pH, anti-inflammatory modulation, facilitating clearance. Dysbiosis, often characterized by dominance iners overgrowth anaerobic bacteria, fosters chronic inflammation, cytokine imbalance, microenvironment conducive progression. Hormonal changes menopause exacerbate these shifts, increasing risk lesions. suggest profiles antimicrobial peptides significantly influence further infection outcomes. Conclusions: The is critical determinant outcomes, for enhance responses prevent Personalized microbiome-targeted therapies may offer novel avenue managing reducing cancer incidence.
Language: Английский
Citations
0
GYNECOLOGY, Journal Year: 2025, Volume and Issue: 27(1), P. 4 - 11
Published: March 1, 2025
Background. Vaginal infection complicates the course of pregnancy and adversely affects perinatal outcomes for mother fetus. With global increase in microorganism resistance to antimicrobial drugs, treatment vaginitis pregnant women is not always effective, leading recurrent pathology. Therefore, seeking new therapeutic solutions a pressing task. Aim. To evaluate effectiveness form benzyl-dimethyl [3-(myristoylamino) propyl] ammonium chloride monohydrate (Miramistin® suppositories) women. Materials methods. A prospective study included 60 with confirmed diagnosis nonspecific vaginitis. All patients received therapy Miramistin® suppositories vaginally once day 7 days. Clinical dynamics microbiological characteristics vaginal biotope were assessed. Results. Disappearance or significant reduction clinical symptoms was noted 96.7% within two days from start treatment. The duration relapse-free period more than 4 weeks. No adverse drug reactions observed. There high satisfaction results among both physicians patients. Conclusion. Treating using an effective method controlling infection.
Language: Английский
Citations
0
Journal of International Medical Research, Journal Year: 2025, Volume and Issue: 53(4)
Published: April 1, 2025
Successful embryo implantation relies on quality, endometrial receptivity, and the synchronized development of both. In recent years, methods for assessing receptivity have considerably advanced, shifting from traditional imaging techniques to modern molecular biology approaches. The evaluation thickness, morphology, subendometrial blood flow, peristalsis before has become less prominent, whereas markers such as pinopodes, integrin αvβ3, its ligand osteopontin, homologous box gene A10 are widely used in clinical practice receptivity. To provide a comprehensive overview, this narrative review systematically searched PubMed Web Science studies assessment infertile women over past two decades, with focus both experimental research. This examined advancements morphological markers, receptivity–related genes, microbiota, other emerging indicators, emphasizing their potential optimizing improving success rates assisted reproductive technologies. Notably, array testing uterine microbiome analysis gained substantial attention personalized diagnosis treatment. aims scientific insights precise infertility diagnostics individualized treatment strategies while offering recommendations future research development.
Language: Английский
Citations
0
Published: July 9, 2024
Recurrent Pregnancy Loss (RPL) affects 1-2% of women, and its triggering factors are unclear. Several studies have shown the vaginal, endometrial, gut microbiota may play a role in RPL. A decrease quantity Lactobacillus crispatus local has been associated with an increase (vaginal endometrial) inflammatory response immune cell activation that leads to pregnancy loss. The be triggered by gram-negative bacteria, lipopolysaccharides (LPS), viral infections, mycosis, or atypia (tumor growth). Bacterial structures metabolites produced could involved modulation responsible for molecular mimicry. Gut metabolic products amount circulating pro-inflammatory lymphocytes, which, turn, will migrate into vaginal endometrial tissues. Local proinflammatory Th1 Th17 subpopulations along Treg tolerogenic NK cells accountable modulate increasing success. Analyzing necessary characterize some RPL patients. Although oral supplementation probiotics not modify microbiota, it benefit transplantation vagina enhance required achieve normal pregnancy. effect hormone stimulation progesterone maintain early on adequately studied, more research is needed this area. Well-designed clinical trials ascertain
Language: Английский
Citations
2
Microorganisms, Journal Year: 2024, Volume and Issue: 12(8), P. 1641 - 1641
Published: Aug. 10, 2024
Recurrent Pregnancy Loss (RPL) affects 1–2% of women, and its triggering factors are unclear. Several studies have shown that the vaginal, endometrial, gut microbiota may play a role in RPL. A decrease quantity Lactobacillus crispatus local has been associated with an increase (vaginal endometrial) inflammatory response immune cell activation leads to pregnancy loss. The be triggered by gram-negative bacteria, lipopolysaccharides (LPS), viral infections, mycosis, or atypia (tumor growth). Bacterial structures metabolites produced could involved modulation responsible for molecular mimicry. Gut metabolic products amount circulating pro-inflammatory lymphocytes, which, turn, will migrate into vaginal endometrial tissues. Local Th1 Th17 subpopulations Treg tolerogenic NK cells accountable modulate response, increasing success. Analyzing necessary characterize some RPL patients. Although oral supplementation probiotics not modify microbiota, it benefit transplantation vagina enhance required achieve normal pregnancy. effect hormone stimulation progesterone maintain early on adequately studied, more research is needed this area. Well-designed clinical trials ascertain
Language: Английский
Citations
2
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 376, P. 1190 - 1208
Published: Nov. 12, 2024
In spite of multipurpose technologies offering broad-spectrum prevention for sexually transmitted infections (STIs) and contraception, the STIs incidences rise worldwide. The situation is even more alarming considering continuous in antimicrobial resistance (AMR) that limits therapy options. this review we address specific challenges efficiently treating vaginal locally, at infection site, by understanding underlying barriers to efficient treatment such as biofilms. Knowledge on biofilms remains, up now, rather scarce requires attention. We therefore propose a 'back basics' insight seeks probe complexity role microbiota, its relationship with implications future therapeutic modalities utilizing advanced nano delivery systems. Our key objective highlight interplay between biofilm, (nano)formulation outcome than provide an overview all nanoformulations were challenged against focused anatomy female reproductive organ physiological changes from birth, unique microenvironment premenopausal postmenopausal women, biofilm current nanomedicine-based approaches treat site. Finally, offer our perspectives associated considerations can aid design development safer potent products persisting infections.
Language: Английский
Citations
1
Journal of Reproductive Immunology, Journal Year: 2024, Volume and Issue: 166, P. 104325 - 104325
Published: Sept. 6, 2024
Language: Английский
Citations
0
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(11), P. 1445 - 1445
Published: Oct. 29, 2024
Bacterial vaginosis (BV), an infection caused primarily by
Language: Английский
Citations
0